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| INTRODUC TI ON
Over the last decades, several drugs have been introduced for the management of Crohn's disease and ulcerative colitis, being the two main phenotypes of IBD.
1 Novel costly pharmaceutical agents (primarily biologicals) have been developed, although with limited data on long-term usage and specific safety issues. 2, 3 Nevertheless, there has been a growing interest in optimisation of conventional drugs for the treatment of IBD patients. 4, 5 One of these drugs was tioguanine, an alternative thiopurine-derivative, which has shown promising therapeutic results in the treatment of both Crohn's disease and ulcerative colitis. [6] [7] [8] Especially in IBD patients who failed prior therapy with conventional thiopurines, that is azathioprine or mercaptopurine, tioguanine has been reported to be both effective as well as tolerated in up to 80%. 7, 9, 10 Potential benefits of tioguanine over conventional thiopurines have been ascribed to pharmacokinetic differences between the thiopurine-derivatives ( Figure   1 ). 11, 12 Unlike azathioprine and its metabolite mercaptopurine, tioguanine is metabolized in fewer metabolic steps and bypasses several intermediate metabolites, possibly evading associated adverse events. 13 Despite the slowly growing evidence of the therapeutic advantages of tioguanine in IBD, there appears to be a reluctance to its use in clinical practice.
14 Association between high dosed tioguanine and hepatotoxicity, in particular nodular regenerative hyperplasia, has been reported. 15 Presuming publication bias on the balance between effectiveness and safety profile, limited and precarious research on tioguanine in IBD patients has been continued and additional data on toxicity have become available. 6 Prevalence of histological liver alterations, such as nodular regenerative hyperplasia, has been low on uncharted, but adequate dosing (0.2-0.3 mg/kg, though not exceeding 25 mg/d) and has appeared to have an asymptomatic course in general. [16] [17] [18] Following these results, tioguanine has been conditionally licensed as a certified IBD treatment in the Netherlands since 2015 for patients who previously failed azathioprine or mercaptopurine due to intolerable adverse events or nonresponse. 8 Azathioprine and mercaptopurine, both as monotherapy or in combination with anti-tumour necrosis factor (TNF) drugs, are well established drugs in the management of both Crohn's disease and ulcerative colitis. These drugs are effective in the maintenance of remission of active IBD and exert steroid-sparing effects. 19, 20 Also, early start of thiopurines reduces risk of first and recurrent abdominal surgery. 21 Long-term use of thiopurines, however, has been associated with an increased risk for opportunistic infections, nonmelanoma skin cancer and lymphoproliferative disorders. 22 These risks increase in patients with combination therapy with corticosteroids and biologicals. 23 Similar data on the long-term safety profile of tioguanine are limited, presumably due to the short duration of the follow-up which has been reported in literature until now. 6, 10 Moreover, utility of therapeutic drug monitoring during tioguanine treatment has not been verified yet.
In view of the increasing use of tioguanine as an alternative drug for IBD, in particular in the Netherlands, more studies evaluating the long-term effects of tioguanine during longer follow-up periods are
warranted. The primary aim of this study was to assess long-term safety and effectiveness profile in relation to therapeutic drug monitoring of tioguanine in IBD patients among three real-life cohorts from tioguanine expert centres in the Netherlands. Furthermore, we evaluated if outcomes have been related to disease and treatment characteristics and performed a meta-analysis of the sustained clinical effectiveness of tioguanine of at least 1 year in IBD patients.
| MATERIAL S AND ME THODS

| Study design and patient population
This was a nationwide, multicentre, retrospective cohort study using data from three tioguanine expert centres located in the western (Amsterdam UMC, location VU medical centre at Amsterdam), F I G U R E 1 Simplified metabolism of thiopurines in a target cell. Bold lines represent the purine salvage pathway in which the pharmacologically active end-metabolites (6-thioguanine nucleotides (6-TGN) are formed and dotted lines represent the competing pathways. The 6-TGNs consist of 6-thioguanine monophosphate (6-TGMP), 6-thioguanine diphosphate (6-TGDP) and 6-thioguanine triphosphate (6-TGTP). The 6-TGTP nucleotides target Rac1 and induce T-cell apoptosis. AZA: azathioprine; MP: mercaptopurine; TPMT: thiopurine S-methyltransferase; 6-MMP: 6-methylmercaptopurine; 6-MMPR: 6-methylmercaptopurine ribonucleotides; HGPRT: hypoxanthine-guanine phosphoribosyltransferase; IMPDH: inosine monophosphate dehydrogenase; GMPS: guanosine monophosphate synthetase; TG: tioguanine; 6-MTG: 6-methylthioguanine 
| Clinical effectiveness
| Drug withdrawal and adverse events
Occurrence of adverse events and reasons for withdrawal during the entire follow-up were recorded. Adverse events were defined as symptoms, signs or laboratory abnormalities that occurred after initiation of tioguanine and were listed according to the common terminology criteria for adverse events (CTCAE) (Version 5.0, released November 27, 2017). 29 The CTCAE are a set of criteria for the standardised classification of adverse events of chemotherapeutic drugs using a range of grades from 1 to 5 (1: mild, 2: moderate, 3: severe, 4:
life-threatening and 5: adverse event-related death). Additionally, we collected all available histopathological evaluations of liver biopsies after initiation of tioguanine until end of follow-up.
| Thiopurine metabolites
In all centres, tioguanine metabolites were determined in red blood cells (RBC) using a method by Dervieux and Boulieu. 30 Due to a lack of standardised operating procedures for measuring thiopurine metabolites, we considered that analysed 6-TGN concentrations might differ between the three hospital laboratories. 31, 32 To evaluate possible differences in 6-TGN concentrations, blood samples were cross-checked between the participating hospitals. 6-TGN concentrations were comparable between the laboratories of Zuyderland medical centre and Rijnstate hospital. However, the laboratory of Amsterdam UMC assessed 6-TGN concentrations that were 1.2 times higher than the other two hospitals. Therefore, collected 6-TGN data of Amsterdam UMC were corrected with a factor 0.83 before data analysis.
| Statistics
Data were presented as numbers with percentages, medians with interquartile range (IQR) or means with standard deviations, when appropriate. Depending on the distribution, parametric or nonparametric tests including the Mann-Whitney U, Wilcoxon signed-rank test, Kruskal-Wallis and the student t test or for categorical variables the chi-square test, were used to test for differences within and between groups. To analyse the association between clinical response and 6-TGN concentrations, a quartile analysis was performed. To this end, 6-TGN concentrations were subdivided in quartiles and its association with clinical response was tested with a chi-square test.
In addition, a receiver operator characteristic (ROC) curve was made.
Cut-off for 6-TGN threshold concentrations was chosen based on a test specificity of ± 90%. A Kaplan-Meier survival curve was used for the comparative analysis of drug survival.
Furthermore, a meta-analysis of the sustained clinical effectiveness of tioguanine after a continued use of at least 12 months was conducted to identify a long-term treatment effect. Data from our study were combined with results of previous studies in which long-term clinical effectiveness of ≥12 months was described. To avoid overlap of included patients, previous studies from our research group were excluded from the meta-analysis. 33, 34 Sustained clinical effectiveness to therapy was reported as the proportion of patients with ongoing clinical effectiveness of tioguanine for at least 12 months relative to all compared patients in the study population.
Pooled proportion with associated 95% CI was calculated using the random effects model to account for possible heterogeneity between the studies. Heterogeneity was assessed by the χ 2 and I 2 tests:
the χ 2 test was used to assess the presence of heterogeneity and the I 2 test was used to determine the percentage of heterogeneity due to variation between studies. The GRADE guidelines were used to assess the quality of evidence of the included articles. 35 Statistical analyses were performed using SPSS Statistics (version 22.0, IBM, New York, NY, USA) and the meta package for R Version 3.2.5 (R foundation for Statistical Computing, Vienna, Austria). Two-tailed probability (P) values < 0.05 were considered statistically significant.
| Ethical considerations
The research medical ethics committee (REC) of the Amsterdam UMC, Zuyderland medical centre and Rijnstate hospital approved this study with file-number 2017-274. The study protocol conforms to the ethical guidelines of the Declaration of Helsinki (2013) as reflected in a prior approval by the institution's human research committee. As data were anonymously provided, written informed consent for data analysis and reporting was waived by the REC.
| RE SULTS
| Patient and therapy characteristics
A total of 305 patients treated with tioguanine for IBD were identified, of whom 31 cases were excluded ( Figure 2 ). In this remaining cohort of 274 patients, 85 patients (31%) were recent users and 189 patients (69%) regular users. The patient characteristics, which were in general similar between the three hospitals, are summarised in 
| Clinical effectiveness
Clinical effectiveness of tioguanine therapy was documented in 182 of 274 patients (66%) within 6 months. In 16 patients (6%), primary clinical response was insufficiently documented. Therapeutic response after these 6 months was reported in another 13 patients (5%). Response rates did not depend on gender (male: 60% and female: 70%, P = 0.17), type of IBD (ulcerative colitis: 72%, Crohn's disease: 65% and IBD unclassified: 50%, P = 0.33) or the indication for tioguanine (induce remission: 66%, maintain remission: 68% or as a concomitant drug in biological therapy: 57%, P = 0.82). Among the entire cohort, a biochemical response at 6 months was observed based on the decrease in ESR, CRP, WBC and FCP and increase in haemoglobin and albumin compared to baseline (Table 2 ). Loss of response did not depend on the prior indication for tioguanine therapy, disease characteristics, gender or age.
| Sustained clinical effectiveness
Sustained clinical effectiveness of at least 12 months of tioguanine has been reported in five previous studies outside of our own research group. The main results of these studies are depicted in Table 3 and were included in a meta-analysis together with the results of this current study. In total, 483 patients with tioguanine therapy for IBD were described. Of these, 231 patients experienced an ongoing clinical effect of tioguanine therapy of more than 12 months (pooled proportion: 44%, 95% CI: 34%-55%) ( Figure 3 ).
The heterogeneity between the studies was 74%.
| Drug survival
The 
| Adverse events
In 112 patients (41%), a total of 186 adverse events were reported during 1567 patient-years of follow-up of tioguanine therapy. Several patients reported more than one adverse event. Adverse events are listed and graded according to the CTCAE in Table 4 Gastrointestinal, general, musculoskeletal and skin-related adverse events contributed to almost half of all the adverse events reported in this cohort (46%), but occurred only graded as mild or moderate according to the CTCAE (Table 4) . Severe adverse events 
| Hepatobiliary disorders
Drug-induced liver injury occurred relatively frequently (n = 51, 19%) in this cohort primarily consisting of patients intolerant for conventional thiopurines, but was mainly mild. Severe cases were limited to two cases (1%). Among the entire cohort, liver enzymes prior to tioguanine did not differ from concentrations at 6 months tioguanine therapy (AST 20 vs 22 U/l, ALT 22 vs 21 U/l, GGT 23 vs 18 U/l, AP 73 vs 77 U/l, bilirubin 6 vs 7 U/l, all P > 0.1) ( Table 2) . 
| Infections and malignancies
Infections necessitating hospitalisation occurred in three patients 
| Therapeutic drug monitoring
| D ISCUSS I ON
In this study, we reported on long-term effectiveness, safety and therapeutic drug monitoring data of tioguanine in three cohorts of IBD patients from tertiary referral centres spread over the Netherlands with a median follow-up over 4 years and 1567
TA B L E 2 Laboratory parameters prior to tioguanine and at 6 mo of continued therapy The therapeutic benefit of tioguanine for IBD has been reported in multiple studies, although with varying response ratios ranging from 22% to 80%. 7 On the other hand, tioguanine has been associated with hepatotoxicity, particularly nodular regenerative hyperplasia, a finding which has been at least partly based on publication bias. 15, 36 In this cohort, drug-induced liver injury occurred in about 20% of patients. Out of this, 96% was graded as mild or moderate according to the CTCAE. Hepatic adverse events graded as severe occurred in two cases. Furthermore, three patients developed symptoms of portal hypertension including a patient with hepatic sarcoidosis and another with primary sclerosing cholangitis.
We attribute these to the underlying conditions which are associated with portal hypertension as one of their most common complications. 37, 38 Portal hypertension in the third patient might be 6 This study affirms that a median daily dosage of 20 mg appears to be relatively safe for the longterm treatment of IBD. 39 Interestingly, we observed the reversibility of vascular liver abnormalities after thiopurine cessation in one of the patients, an observation which has been reported before. 18, 36 In contrast to conventional thiopurines, data on the utility of therapeutic drug monitoring of 6-TGN measurements during tioguanine treatment are sparse. 40 In the present study, we observed that combination of various parameters including the biochemical, radiological, histological, endoscopic and pathophysiological findings and physician's global assessment, hence, was semi-standardised. Finally, we combined our long-term results with previous published data to compute a pooled proportion for the sustained clinical effectiveness of tioguanine for IBD. This meta-analysis was limited by large heterogeneity among the studies of 74% and lack of sufficient quality of the included studies.
In conclusion, the therapeutic benefit of tioguanine needs to be balanced with associated toxicity when considering a role for this thiopurine-derivative in IBD treatment. In this large cohort, prolonged tioguanine therapy was well tolerated and effective as a maintenance treatment for IBD. Approximately 70% of patients continued tioguanine therapy during a median time of more than 4 years. Adverse events were common, but were mostly clinically tolerable. Intolerable or severe adverse events leading to withdrawal were reported in 11% patients, mainly in patients who recently started tioguanine therapy. 
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